TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers

Diabetic Foot Ulcer Clinical Trial

Official title:

TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00389636
• Other study ID #: SS-0601
• Status: Active, not recruiting
• Phase: N/A
• First received: October 18, 2006
• Last updated: May 5, 2008
• Start date: September 2006
• Est. completion date: July 2008

Study information

• Verified date: May 2008
• Source: Soluble Systems, LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Patients will be randomized to receive TheraGauze alone or with Regranex to treat diabetic foot ulcer condition. The purpose of the study is provide the sponsor with pilot information regarding the ability of TheraGauze to promote wound healing on its own and to examine synergy with Regranex in the treatment of diabetic foot ulcers.

Description:

This study will evaluate the use of TheraGauzeT (Soluble Systems, LLC) wound dressing, a polymer hydrogel chemically impregnated into a rayon/polyester formed fabric, forming a pliable, conforming solid matrix. TheraGauze is FDA Class I exempt (regulation #21CFR, product code 5878.4022). It is hypothesized that this material will be useful for the treatment of full-thickness diabetic ulcers. It is further hypothesized that this material will enhance the action of Regranex (becaplermin) gel by providing an optimal environment for this growth factor to function. This study will observe patient outcomes following diabetic foot ulcer treatment with TheraGauze and with or without the use of Regranex.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: July 2008
• Est. primary completion date: July 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria: Patients

• who are 18 years old or older;

• who are diagnosed as having insulin-dependent or non-insulin-dependent diabetes mellitus (5.5% <HgBA1C<12%);

• who have foot ulcers extending through the epidermis and dermis but not with exposed tendon or bone;

• who have a diagnosis of chronic diabetic ulcer;

• who have a viable wound bed with granulation tissue as determined by bleeding following debridement;

• who have an ulcer size which is at least 1 cm2 and no greater then 16cm2;

• who have signed an informed consent form.

• who have a wound that has been present for at least 4 weeks at the time of screening.

Exclusion Criteria: Patients

• having ulcers less than 1cm2 or greater than 16cm2 in size;

• having severe arterial disease (ankle brachial index (ABI) less than 0.65);

• having history of radiation therapy to the ulcer site;

• who use corticosteroids >10mg prednisone daily

• who use any immune suppressive, or severely immunocompromised patients;

• who have an ulcer that was of a non-diabetic pathophysiology;

• having vasculitis, severe rheumatoid arthritis, or other collagen vascular disease;

• having malnutrition (defined by albumin <2.5 g/dL);

• having a known allergy or hypersensitivity to the components of either TheraGauze or Regranex;

• having erythema or purulence associated with a severe infection of the wound site;

• having signs and symptoms of cellulitis, osteomyelitis, necrotic or avascular ulcer beds;

• undergoing hemodialysis;

• having uncontrolled diabetes (defined as HgB A1c>12%)

• having deficient blood supply to ulcers (defined as capillary fill time >3 seconds at tips of toes)

• having Charcot's neuroarthropathy as determined by clinical and/or radiographic examination;

• having sickle cell disease;

• having exposed bone, tendon, or fascia;

• who are currently enrolled in a clinical evaluation of another investigational device or drug, or have received and investigational treatment for diabetic foot ulcers in the last 30 days;

• unable to comply with the procedures described in the protocol.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetic Foot
• Diabetic Foot Ulcer
• Foot Ulcer
• Ulcer

Intervention

Device:
• TheraGauze
TheraGauze

Drug:
• Regranex
Regranex + TheraGauze

Locations

Country	Name	City	State
United States	Northwestern University	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Soluble Systems, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of complete wound healing within 12 weeks
Primary	Time to complete wound healing within 12 weeks
Secondary	Investigator's or clinician's assessment of wound quality (ulcer duration, baseline area, staging, presence of fibrin or granulation tissue)
Secondary	Patient's assessment (pain, itching)
Secondary	Presence of epithelialization visible on the wound surface
Secondary	Occurrence of infection at the wound site
Secondary	Recurrence of ulcer during the 20 week follow-up period
Secondary	Adverse events (infection, cellulites, seroma, etc.)
Secondary	Excess pain